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Background and aims: Alcohol consumption is an important risk factor for cardiovascular morbidity and mortality 
worldwide. The highest levels of alcohol consumption are observed in Europe, where alcohol as contributing 
cause of coronary heart disease (CHD) is also most significant. We aimed to describe alcohol consumption 
patterns across European regions and adherence to the current guidelines in patients with a recent CHD event. 
Methods: The ESC-EORP survey (EUROASPIRE V) has been conducted in 2016–2017 at 131 centers in 27 Eu-
ropean countries in 7350 patients with a recent CHD. Median alcohol consumption, as well as the proportion of 
abstainers and excessive drinkers (i.e. >70 g/week for women and >140 for men, as recommended by the 
European guidelines on cardiovascular prevention), was calculated for each region. To assess adherence to 
guidelines, proportions of participants who were advised to reduce excessive alcohol consumption and partici-
pants who were incorrectly not advised were calculated per region. 
Results: Mean age was 64 years (SD: 9.5), 75% were male. Abstention rates were 53% in males and 77% in fe-
males, whereas excessive drinking was reported by 9% and 5% of them, respectively. Overall, 57% of the par-
ticipants were advised to reduce alcohol consumption. In the total population, 3% were incorrectly not advised, 
however, this percentage differed per region (range: 1%–9%). In regions where alcohol consumption was 
highest, participants were less often advised to reduce their consumption. 
Conclusion: In this EUROASPIRE V survey, the majority of CHD patients adhere to the current drinking guide-
lines, but substantial heterogeneity exists between European regions.   
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1. Introduction 
According to the most recent Global Burden of Disease Study, alcohol 
consumption is the seventh leading risk factor for both deaths and 
disability-adjusted life years (DALYs) [1], accounting for 5.3% of all 
deaths and 5.1% of all DALYs worldwide [2]. For cardiovascular disease 
(CVD), including coronary heart disease (CHD), specifically - the leading 
cause of mortality globally - the alcohol-attributable burden was esti-
mated at 593,000 deaths (3.3% of all CVD deaths) and 13 million CVD 
DALYs (3.2% of all CVD DALYs). Alcohol consumption was particularly 
a factor of interest in Europe, where alcohol as contributing cause of 
CVD was highest and accounted for 10.5% of all CVD deaths and 11.0% 
of CVD DALYs [2]. 
Estimating the total alcohol-attributable CVD burden is complex 
since it is a composition of detrimental and protective effects: heavy 
alcohol consumption is always a risk factor for disease [3], however, low 
to moderate alcohol consumption is associated with lower mortality 
from ischemic CVD, but not from hemorrhagic stroke and hypertensive 
cardiac disease [4,5]. The association of moderate alcohol intake ap-
pears to be similar among individuals at both low and high cardiovas-
cular risk and also among those with prevalent CVD [6,7]. The potential 
beneficial effects of low to moderate alcohol consumption are still 
debated in the scientific literature [3,8]. 
The European guidelines on cardiovascular prevention in clinical 
practice of 2016 discourage the consumption of alcoholic beverages in 
general and otherwise advise to limit consumption to two units of 
alcohol a day for men and one unit of alcohol a day for women [9]. The 
guidelines additionally provide a comprehensive overview on how to 
reduce excessive alcohol consumption by population-based strategies. 
However, previous research on physicians’ perceptions on alcohol 
screening has shown that knowledge of the guidelines still needs 
improvement [10,11]. 
Implementation of the European guidelines on cardiovascular pre-
vention has been repeatedly evaluated by the ESC-EORP (European 
Society of Cardiology – EurObservational Research Program) EURO-
ASPIRE (European Action on Secondary and Primary Prevention by 
Intervention to Reduce Events) surveys [12–16]. However, to date, no 
information on alcohol consumption specifically in coronary patients 
has been published from these surveys, while it has been demonstrated 
that alcohol consumption patterns in CVD patients differ from those of 
the general population [17,18]. This report describes patterns of alcohol 
consumption across different European regions and adherence to the 
current guidelines in patients with a recent acute coronary event or 
revascularization procedure based on the EUROASPIRE V survey. 
2. Patients and methods 
2.1. Study population 
The EUROASPIRE V survey has been conducted in 2016–2017 at 131 
centers in 27 European countries. In each country, up to three 
geographical areas with a population greater than half a million in-
habitants were selected and all hospitals in the area were identified, to 
ensure representativeness. The interview response rate was 56%. Details 
of this study have been described elsewhere [14]. In short, 8261 CHD 
patients aged between 18 and 80 years were interviewed six months up 
to two years after a first or recurrent clinical diagnosis or treatment of (i) 
elective or emergency coronary artery bypass grafting (CABG), (ii) 
elective or emergency percutaneous coronary intervention (PCI), (iii) 
acute myocardial infarction (MI) (ICD-10 I21) or (iv) acute myocardial 
ischemia (ICD-10 I20). The visit included an interview, a physical ex-
amination and a blood sample collection. National coordinators for 
EUROASPIRE V obtained approvals from local ethics committees. 
Informed consent was obtained from each participant by means of a 
signed declaration. 
In the present analysis, participants with insufficient data on alcohol 
consumption were excluded (n = 205). Furthermore, participants from 
countries not classified as European territory according to the United 
Nations Geoscheme [19] (i.e. Egypt, Kyrgyzstan) were excluded from 
further analyses (n = 706). The analytical sample included 7350 par-
ticipants. Data on adherence were missing for 190 (2.6%) participants, 
therefore, the assessment of adherence to guidelines was performed in 
7160 participants. 
2.2. Assessment of alcohol consumption 
Current or former alcohol consumption since the index event was 
self-reported using a beverage specific quantity-frequency question-
naire, in which participants had to report the frequency of drinking 
(monthly, weekly or daily) and the number of beverages they consumed 
during this time period separately for beer, wine, spirits and “other” 
(country-specific) beverages. The volume of one drink was defined as 30 
ml of spirits (which is equivalent to 10 g of alcohol), 125 ml of wine (12 g 
of alcohol) and 375 ml of beer (15 g of alcohol). The “other beverages” 
category contained volumes equivalent to 10 g of alcohol. We calculated 
the total and beverage-specific alcohol consumption in grams/week. 
Based on this weekly alcohol consumption, we defined consumption 
categories for men and women separately, as the guidelines provide sex- 
specific recommendations. In the European guidelines, a standard 
serving of an alcoholic beverage contains 10 g of alcohol [9]. We cate-
gorized male drinkers into: lifetime abstention, former drinkers or cur-
rent drinkers (light (0–70 g/week), moderate (70–140 g/week) or heavy 
(>140 g/week)). For women the categories for current drinkers were: 
light (0–35 g/week), moderate (35–70 g/week) or heavy (>70 g/week). 
Adherence to guidelines was assessed by the question: “Since the 
index event, were you offered any personal advice by a doctor or other 
health professional on reducing excessive alcohol intake?” (yes/no). 
Excessive intake is interpreted as > 140 g/week for men, > 70 g/week 
for women, in line with the European guidelines. Consecutively, to 
evaluate whether this recommendation was followed, participants were 
asked whether they had reduced excessive alcohol intake since the index 
event to decrease their risk of recurrent coronary events (yes/no). 
2.3. Covariates 
Information on personal and demographic details and the type of 
index event or procedure was obtained from medical records. Smoking 
status was defined as self-reported smoking and/or a breath carbon 
monoxide exceeding 10 ppm by means of Smokerlyzer® (Bedfont Sci-
entific, Model Micro+) [20]. Education level was self-reported and 
categorized into the following categories: low (primary school 
completed), middle (high/secondary school completed or intermediate 
between secondary school and university) and high (college/university 
completed or post-graduate degree). The physical activity target was 
defined by the following question: ‘‘Do you take regular physical activity 
of at least 30 min’ duration on average five times a week?’’ Finally, 
participants were asked whether they had been hospitalized for other 
cardiovascular events before the index event (yes/no). 
During the examination, height and weight were measured in light 
indoor clothes without shoes (SECA scales 701 and measuring stick 
model 220). Body mass index (BMI) was calculated as measured weight 
in kilograms divided by the square of height in meters. Blood pressure 
was measured twice using an automatic digital sphygmomanometer 
(Omron M6) and the mean was used for the analyses. 
A venous blood sample was drawn for serum total cholesterol, high- 
density cholesterol (HDL-C), triglycerides, glycated haemoglobin 
(HbA1c) and creatinine. All measurements were performed on a clinical 
chemistry analyzer (Architect c8000; Abbott Laboratories, Abbott Park, 
Illinois, USA). Total cholesterol, HDL-C, and creatinine were analyzed in 
serum, and HbA1c in whole blood. Low-density cholesterol (LDL-C) was 
calculated by Friedewald’s formula [21]. Estimated glomerular filtra-
tion rate was calculated using the Chronic Kidney Disease Epidemiology 
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Collaboration equation (CKD-EPI) [22]. 
We defined hypertension as either previously diagnosed hyperten-
sion as described in medical records or a blood pressure at the exami-
nation ≥ 140/90 mmHg (≥ 140/85 mmHg in people with diabetes) [9]. 
Similarly, diabetes was defined as either a documented diagnosis of 
diabetes or an HbA1c ≥ 6.5% [9]. Finally, hypercholesterolemia was 
defined as documented dyslipidemia or an LDL-C ≥ 1.8 mmol/L. If 
LDL-C was not available, a total cholesterol > 6.5 mmol/L was regarded 
as hypercholesterolemia. 
2.4. Statistical analysis 
All statistical analyses were performed using IBM SPSS 25.0 for 
Windows and R version 3.5.1. We tabulated demographic and lifestyle 
factors, as well as the presence of comorbidities and prior cardiovascular 
events, stratified by alcohol consumption category. 
Furthermore, we examined alcohol consumption per European re-
gion, both as a continuous outcome (median alcohol consumption in 
grams/week in current drinkers only) and as a categorical outcome, 
using the previously defined consumption categories. Countries were 
allocated to one of the four subregions of Europe, according to the 
United Nations Geoscheme [19]: Western Europe (Netherlands, 
Belgium, Germany), Northern Europe (United Kingdom, Ireland, Swe-
den, Finland, Latvia, Lithuania), Southern Europe (Spain, Portugal, 
Italy, Greece, Bosnia & Herzegovina, Croatia, Serbia, Slovenia, Turkey) 
and Eastern Europe (Russian federation, Ukraine, Bulgaria, Czech Re-
public, Poland, Romania, Kazakhstan) (Supplementary Fig. 1). 
To assess adherence to the European guidelines on cardiovascular 
prevention in clinical practice 2016, we calculated the proportion of 
participants who adhered to the guidelines per European region and 
used the Pearson chi-square test to test for differences between regions. 
Secondly, we examined the proportion that was advised by a health 
professional to reduce their excessive alcohol consumption. We calcu-
lated this proportion both for participants who indicated to adhere to the 
guidelines, and for participants who were still non-adherent (i.e. 
excessive drinkers) at the time of report, stratified by European region. 
Moreover, we calculated the proportion of participants that was incor-
rectly not advised (i.e. the excessive drinkers who were not advised to 
reduce alcohol consumption) per region. Lastly, we examined what kind 
of participants were more often advised to reduce excessive alcohol 
consumption, by analyzing which determinants independently contrib-
uted to the chance of being advised. We performed multivariable logistic 
Table 1 
Patient characteristics of 5502 male EUROASPIRE V participants, by alcohol consumption category.   
Alcohol consumption category 
Never drinker Former drinker 0–70 g/week 70–140 g/week >140 g/week 
Total number of participants 2601 (47.3) 314 (5.7) 1480 (26.9) 628 (11.4) 479 (8.7)  
Age > 65 years 1165 (44.8) 133 (42.4) 668 (45.1) 360 (57.3) 265 (55.4) 
BMI > 30 kg/m2 871 (34.3) 128 (41.2) 565 (38.3) 200 (32.2) 159 (33.3)  
Type of index event 
CABG 271 (10.4) 44 (14.0) 201 (13.6) 96 (15.3) 79 (16.5) 
PCI 1984 (76.3) 216 (68.8) 1112 (75.1) 480 (76.6) 358 (74.7) 
Acute MI without procedure 151 (5.8) 33 (10.5) 69 (4.7) 29 (4.6) 25 (5.2) 
Unstable angina without procedure 195 (7.5) 21 (6.7) 98 (6.6) 22 (3.5) 17 (3.6)  
Smoking status 
Never smoker 762 (29.3) 53 (16.9) 357 (24.1) 145 (23.1) 87 (18.2) 
Former smoker 1351 (51.9) 184 (58.6) 820 (55.4) 368 (58.6) 278 (58.0) 
Current smoker 488 (18.8) 77 (24.5) 303 (20.5) 115 (18.3) 114 (23.8)  
Education 
Low 336 (13.4) 33 (10.6) 151 (10.3) 103 (16.5) 89 (18.7) 
Middle 1567 (62.3) 210 (67.5) 852 (58.2) 358 (57.3) 254 (53.4) 
High 612 (24.3) 68 (21.9) 462 (31.5) 164 (26.2) 133 (27.9)  
Physical activity 
Regular physical activity 861 (33.1) 89 (28.3) 555 (37.5) 248 (39.5) 153 (31.9)  
Prior CVD event 1018 (39.1) 161 (51.3) 616 (41.6) 245 (39.0) 167 (34.9)  
Advised to reduce alcohol consumption 1505 (57.9) 187 (59.6) 889 (60.1) 375 (59.7) 286 (59.8) 
Indicated to have reduced alcohol consumption 1328 (51.1) 198 (63.1) 783 (52.9) 319 (50.8) 225 (47.1)  
Comorbidities 
Diabetes 738 (28.4) 84 (26.8) 337 (22.8) 152 (24.2) 115 (24.0) 
Hypertension 1823 (70.1) 252 (80.3) 1032 (69.7) 429 (68.3) 326 (68.1) 
Hypercholesterolemia 1660 (63.8) 201 (64.0) 932 (63.0) 359 (57.2) 289 (60.3)  
Measurements at examination 
SBP (mmHg) 133 ± 17 135 ± 20 134 ± 18 136 ± 19 137 ± 19 
DBP (mmHg) 80 ± 10 82 ± 11 81 ± 11 80 ± 11 80 ± 11 
Total cholesterol (mmol/L) 4 ± 1 4 ± 1 4 ± 1 4 ± 1 4 ± 1 
HDL (mmol/L) 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 
Hba1c (%) in participants with diabetes 6.9 [6.3, 7.9] 6.8 [6.0, 8.0] 6.7 [6.1, 7.7] 6.8 [6.2, 7.7] 6.4 [5.9, 7.2] 
Hba1c (%) in participants without diabetes 5.5 [5.3, 5.8] 5.6 [5.3, 5.8] 5.5 [5.3, 5.7] 5.5 [5.3, 5.7] 5.4 [5.2, 5.7] 
eGFR (mL/min/1.73m2) 79 ± 20 78 ± 19 79 ± 17 78 ± 19 78 ± 18 
Values represent numbers (percentages); means ± standard deviations; medians [interquartile ranges]. 
BMI (body mass index), CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), MI (myocardial infarction), CVD (cardiovascular disease), SBP 
(systolic blood pressure), DBP (diastolic blood pressure), HDL (high-density cholesterol), Hba1c (glycated haemoglobin), eGFR (estimated glomerular filtration rate). 
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regression analysis with “being advised to reduce excessive alcohol 
consumption” as the outcome variable. As determinants, we included: 
age > 65, sex, obesity (BMI > 30), smoking status, education level, 
history of a prior CVD event, diabetes, hypertension and hypercholes-
terolemia. We performed this analysis both in the total population and in 
that part of the population that was currently non-adherent to the 
guidelines (i.e. the currently excessive drinkers). 
3. Results 
3.1. Participant characteristics 
Among 7350 EUROASPIRE participants mean age was 64 years (SD 
= 9.5), which did not materially differ between European regions. The 
overall proportion of female participants was 25%. Particularly in 
Western Europe, this proportion was smaller, with only 19% of the 
population being female (Supplementary Table 1). 
Abstention was reported by 53% of the male participants and 77% of 
the female participants. As compared to lifetime abstainers and current 
drinkers, former drinkers more often had a positive history of cardio-
vascular events before the index event and more often suffered from 
diabetes or hypertension. Moreover, former drinkers most often re-
ported to have reduced their alcohol consumption (Tables 1 and 2). 
3.2. Alcohol consumption per region 
Median alcohol consumption in current male drinkers was 53 g/ 
week (25–75 percentile 19–108), which is approximately equal to five 
standard units per week. Alcohol consumption tended to be the highest 
in Western and Southern Europe (Fig. 1). Preference for beverage type 
differed among the European regions: male participants in Southern 
Europe showed a preference for wine, whereas in the other regions 
consumption of beer was most prevalent (Fig. 1). Current female 
drinkers consumed less alcohol than men, with a median consumption of 
20 g/week (25–75 percentile 6–60), equal to 2 standard units per week. 
Wine was the most consumed type of alcoholic beverage in females 
across all European regions (Fig. 1). 
Abstention rates differed per European region. In both men and 
women, abstention rates were highest in Southern and Eastern Europe. 
Western Europe showed the highest proportion of moderate to heavy 
drinkers, followed by Northern Europe (Fig. 2). 
Table 2 
Patient characteristics of 1848 female EUROASPIRE V participants, by alcohol consumption category.   
Alcohol consumption category 
Never drinker Former drinker 0–35 g/week 35–70 g/week >70 g/week 
Total number of participants 1389 (75.2) 39 (2.1) 270 (14.6) 64 (3.5) 86 (4.7)  
Age > 65 years 820 (59.0) 25 (64.1) 149 (55.2) 37 (57.8) 49 (57.0) 
BMI > 30 kg/m2 615 (45.6) 22 (56.4) 115 (42.8) 27 (42.2) 28 (33.7)  
Type of index event 
CABG 120 (8.6) 7 (17.9) 25 (9.2) 8 (12.5) 6 (7.0) 
PCI 999 (71.9) 28 (71.8) 196 (72.6) 52 (81.3) 62 (72.1) 
Acute MI without procedure 113 (8.2) 3 (7.7) 15 (5.6) 2 (3.1) 10 (11.6) 
Unstable angina without procedure 157 (11.3) 1 (2.6) 34 (12.6) 2 (3.1) 8 (9.3)  
Smoking status 
Never smoker 823 (59.3) 18 (46.2) 132 (48.9) 25 (39.1) 35 (40.7) 
Former smoker 368 (26.5) 15 (38.5) 103 (38.1) 30 (46.9) 35 (40.7) 
Current smoker 198 (14.2) 6 (15.3) 35 (13.0) 9 (14.0) 16 (18.6)  
Education 
Low 241 (17.7) 0 (0.0) 34 (12.6) 10 (15.9) 15 (17.4) 
Middle 803 (58.9) 28 (71.8) 164 (60.7) 36 (57.1) 46 (53.5) 
High 319 (23.4) 11 (28.2) 72 (26.7) 17 (27.0) 25 (29.1)  
Physical activity 
Regular physical activity 334 (24.0) 8 (20.5) 82 (30.4) 21 (32.8) 27 (31.4)  
Prior CVD event 514 (37.0) 15 (38.5) 97 (35.9) 14 (21.9) 20 (23.3)  
Advised to reduce alcohol consumption 727 (52.3) 24 (61.5) 131 (48.5) 35 (54.7) 42 (48.8) 
Indicated to have reduced alcohol consumption 679 (48.9) 21 (53.8) 131 (48.5) 29 (45.3) 42 (48.8)  
Comorbidities 
Diabetes 491 (35.3) 12 (30.8) 64 (23.7) 13 (20.3) 20 (23.3) 
Hypertension 1133 (81.6) 30 (76.9) 184 (68.1) 37 (57.8) 61 (70.9) 
Hypercholesterolemia 1208 (87.0) 32 (82.1) 215 (79.6) 51 (79.7) 73 (84.9)  
Measurements at examination 
SBP (mmHg) 135 ± 20 131 ± 18 133 ± 18 131 ± 18 137 ± 19 
DBP (mmHg) 79 ± 12 80 ± 11 79 ± 11 78 ± 10 79 ± 11 
Total cholesterol (mmol/L) 5 ± 1 5 ± 2 5 ± 1 4 ± 1 5 ± 1 
HDL (mmol/L) 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 
Hba1c (%) in participants with diabetes 7.1 [6.3, 8.3] 7.8 [6.4, 10.5] 6.8 [6.1, 8.6] 7.4 [6.6, 8.8] 6.8 [5.7, 7.8] 
Hba1c (%) in participants without diabetes 5.6 [5.4, 5.8] 5.7 [5.5, 5.9] 5.5 [5.3, 5.7] 5.5 [5.3, 5.7] 5.4 [5.2, 5.6] 
eGFR (mL/min/1.73m2) 72 ± 20 74 ± 19 72 ± 19 76 ± 20 75 ± 17 
Values represent numbers (percentages); means ± standard deviations; medians [interquartile ranges]. 
BMI (body mass index), CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), MI (myocardial infarction), CVD (cardiovascular disease), SBP 
(systolic blood pressure), DBP (diastolic blood pressure), HDL (high-density cholesterol), Hba1c (glycated haemoglobin), eGFR (estimated glomerular filtration rate). 
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3.3. Adherence to guidelines 
Overall, 92% of the participants currently adhered to the guidelines. 
This percentage was lower in Western (83%) and Northern (91%) 
Europe and higher in Southern (92%) and Eastern (96%) Europe (p <
0.001). Men were more often non-adherent (9%) as opposed to women 
(5%). 
Supplementary Fig. 2 shows the proportions of participants advised 
to reduce alcohol consumption per region, both for currently adherent 
and currently non-adherent drinkers. The total proportion advised was 
the lowest in Western Europe (32%), followed by Southern Europe 
(54%), Northern Europe (57%) and Eastern Europe (70%). In the total 
population, the proportion that was currently non-adherent and had not 
been advised, hence the proportion that was incorrectly not advised, was 
3%. This percentage was highest in Western Europe (9%) and lowest in 
Eastern Europe (1%). Percentages in Southern and Northern Europe 
were equal (both 3%) (Fig. 3). 
When studying determinants associated with being advised more 
often in the total population, we found a number of independent pre-
dictors: younger people (< 65 years) were more often advised than older 
people. Males more often than females, and higher educated participants 
more often received advice than low educated participants. Moreover, 
participants with comorbidities or obesity were more often advised to 
reduce their alcohol consumption (Supplementary Table 2). Similar 
patterns were found in the non-adherent participants only, however, 
confidence intervals tended to be wider due to the limited number of 
participants in this subgroup (Supplementary Table 2). 
4. Discussion 
In this European cohort of coronary patients with a recent CHD event 
or procedure, 47% of the male and 23% of the female participants re-
ported current alcohol consumption. Overall adherence to drinking 
guidelines (i.e. not more than 2 standard units (20 g)/day for men, and 
not more than 1 standard unit (10 g)/day for women) was 92%. How-
ever, this proportion tended to differ between male and female partici-
pants (9% of the men were excessive drinkers as opposed to 5% of the 
women) and European regions, with the highest proportion of both male 
and female excessive drinkers in Western Europe (17%), followed by 
Northern (9%), Southern (8%) and Eastern Europe (4%). In the total 
population, 57% of the participants were advised to reduce alcohol 
consumption and only 3% were incorrectly not advised. Proportions 
differed per region, with lowest advice rates in Western Europe: 9% 
were incorrectly not advised. Younger, male CHD patients and partici-
pants with comorbidities or obesity were more often advised to reduce 
alcohol consumption. 
4.1. Strengths and limitations 
General population data are available on the epidemiology of alcohol 
consumption in Europe, for example in the World Health Organization 
(WHO) reports on alcohol burden worldwide [2] and in Europe specif-
ically [23]. However, to our knowledge, this is the first report that de-
scribes and compares alcohol consumption in a subpopulation of CHD 
patients across European regions. Additionally, we assessed and quan-
tified adherence to current guidelines both by health professionals and 
patients. 
An important limitation is that we did not have information on 
alcohol consumption patterns prior to the index event. Additionally, 
presumably a proportion of the participants has misinterpreted the 
adherence questions, answering affirmatively if any advice on alcohol 
consumption was given and not only advice on excessive consumption. 
Therefore, we cannot be certain which participants were former exces-
sive drinkers and we can only compare currently adherent and currently 
non-adherent participants. It is likely that the proportion that was 
correctly advised is actually higher in the adherent group, because this 
group also contains the participants who did not need to be advised as 
they were already adherent before the index event. Likewise, the pro-
portion advised in the non-adherent drinkers is likely to be higher, as the 
majority of correctly advised excessive drinkers probably became part of 
the currently adherent group. Generally, these misclassifications will 
have led to an underestimation of adherence to the guidelines. However, 
we were still able to make between-region comparisons. 
Furthermore, the limited number of current alcohol consumers in the 
survey forced us to describe the alcohol consumption per region, instead 
of per country. There is substantial heterogeneity between European 
countries regarding drinking patterns and definition of a standard unit. 
Since the questionnaire only provided one definition of a standard drink, 
the total amount of alcohol consumed might be underestimated or 
overestimated in some countries. Moreover, a quantity-frequency 
questionnaire like the one we used is a valid instrument to measure 
regular alcohol consumption, but tends to underestimate heavy episodic 
Fig. 1. Median alcohol consumption per beverage type in 2468 male and 398 female current drinkers with a recent coronary event, by European region.  
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drinking [24]. In regions where this consumption pattern is more 
prevalent, for example in Eastern Europe [23], alcohol consumption 
might have been underestimated. Lastly, the low interview response rate 
(56%) might have led to an underestimation of the true alcohol con-
sumption, as it is likely that the non-responders more often have an 
unhealthier lifestyle, including heavy or dependent drinking [24,25]. 
4.2. Comparison with other surveys 
Previous studies have described alcohol consumption patterns in 
CVD patients specifically and found comparable current drinking rates 
[26,27]. Helfand et al. compared alcohol consumption patterns in 
women having had a myocardial infarction with healthy women in the 
United States and reported that only 24% of the post-MI women were 
Fig. 2. Distribution of 5502 male and 1848 female participants in alcohol consumption categories, by European region.  
Fig. 3. Distribution of advice given in currently adherent and currently non-adherent participants. 
The proportion non-adherent/not advised is the proportion of the total population that is incorrectly not advised. 
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current drinkers as compared to 46% of the healthy women [17]. This is 
in line with the proportion of current female drinkers that we found in 
our European cohort (22%). In another study in two cohorts of older 
Europeans, differences in current drinking rates between 
post-myocardial patients and healthy peers were found as well, being 
most pronounced in women (34% current drinkers in CVD patients vs 
51% in healthy participants in females compared to 71% vs 79% in 
males) [18]. To our knowledge, no data are available on consumption 
patterns in CHD patients per European region. Therefore, we compared 
our data to the WHO European data on alcohol consumption in the 
general population. According to the WHO report, most alcohol is 
consumed in Eastern Europe, followed by Western Europe. This differs 
from our results in which alcohol consumption in Eastern Europe was 
actually lowest in CHD patients. The WHO uses aggregate data on 
recorded alcohol consumption (e.g. sales data) instead of self-reported 
consumption, in this way capturing also heavy episodic drinking. This 
might be one of the reasons for the differences we found. 
In general, adherence to consumption guidelines was high and the 
proportion that was incorrectly not advised was rather small. Both 
health professionals advising on consumption limits and CHD patients 
following this advice seem to do well in adhering to the European rec-
ommendations. However, still 1 out of 11 male CHD patients drinks 
excessively, so there is definitely more to gain regarding risk factor 
control. Interestingly, the proportion of participants that was advised to 
reduce alcohol consumption was the lowest in the regions where the 
proportion of excessive drinkers was highest. This calls for further 
exploration of perceptions on alcohol consumption of health pro-
fessionals and patients in these regions. As an example, previous 
research has shown that smoking status of the health professional in-
fluences his perspective on smoking cessation: physicians who smoked 
are less likely to advise their patients to quit smoking [28–30]. More-
over, prevalence of smoking among physicians varies widely per country 
[31]. It would be interesting to explore whether the same principle holds 
for alcohol consumption and if it could partly explain our findings. 
4.3. Conclusion 
In conclusion, in this European cohort of CHD patients, the majority 
of participants currently adhered to the alcohol consumption levels 
recommended by the European guidelines, and alcohol consumption 
was lower as compared to the general population. Only a minor fraction 
of the CHD patients was incorrectly not advised to reduce excessive 
consumption. However, there is substantial heterogeneity in Europe. 
Most remarkable is the finding that in regions where alcohol con-
sumption is the highest, participants are less often advised to reduce 
their consumption than in neighboring regions in which excessive 
drinking is less prevalent. 
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